Welcome to the 2026 Pipeline Report. Our annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
All these updates are downloadable PDFs, and we’ll be adding more soon, so please check back. Please feel free to use and share these widely in your scientific, policy, and advocacy work.
HIV
HCV
August 2026
TB
Pipeline reports tracking developments in TB diagnostics, and long-acting technologies will be published later this year.
Antiretroviral Therapy Update*
9/1/2026 post-publication update: The US Food and Drug Administration approved Gilead’s fixed dose once-daily pill containing lenacapavir and bictegravir (trade name Bixlenvo) as a new single-tablet option for the treatment of HIV on August 27, 2026. The Bixlenvo label with prescribing information is available online.